Articles tagged with Chemotherapy
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers developed a novel material that self-assembles into micelle structures targeting cancer cell lysosomes, specifically interacting with Cathepsin B. This leads to dysfunctional lysosomes and apoptotic death of cancer cells. The technology promises a new approach to combat drug resistance in cancer treatment.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
A Brown University team developed a hydrogel-based delivery system that balances tumor acidity and increases doxorubicin's effectiveness against cancer cells. Initial lab tests show promising results, paving the way for pre-clinical trials.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
A large-scale international study of childhood cancer survivors found that women who received high-dose doxorubicin chemotherapy without chest radiation have a significantly increased risk of breast cancer before age 40. The researchers are calling for broadening guidelines for breast cancer screening in these patients.
Researchers at Hollings Cancer Center have made a breakthrough in CAR-T-cell therapy by eliminating the need for lymphodepleting chemotherapy, which reduces the risk of severe side effects. In preclinical models, their method showed promising results in controlling cancer and creating memory cells trained on specific proteins.
A subgroup analysis found that patients with an NPM1 mutation had a 48% reduced risk of death compared to those without the mutation. Patients receiving supplementation experienced lower rates of bacterial infections, bleeding, and inflammation during intensive chemotherapy.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Breast cancer survivors often struggle to take their life-extending medication due to side effects and high costs. A new study found that interventions such as cost-cutting policies, mobile apps, and psychological counseling can increase medication adherence by nearly 1.5 times. Addressing mental health issues, particularly depression,...
Researchers developed a new formulation of doxorubicin that targets cancer cells while reducing cardiotoxicity. The protein-shell encapsulation increases specificity for cancer cells and decreases harm to healthy heart cells.
A new study finds that cost-cutting policy changes, mobile apps, and psychological strategies can increase medication adherence by nearly 1.5 times among breast cancer survivors. The study also highlights the importance of managing side effects through physical therapy, exercise, and behavioral counseling.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
A new targeted treatment called zolbetuximab has been shown to extend survival for patients with advanced gastric or gastroesophageal junction cancer that overexpresses a specific biomarker. The treatment significantly increased progression-free and overall survival, with improved results compared to standard chemotherapy.
Researchers found that certain anti-cancer compounds cause distinct nucleolar shapes and stress, which can be measured using a new classification system. This discovery could lead to improved understanding of why some drugs fail in clinical trials, providing a potential tool for identifying promising drug candidates.
Researchers developed SQUID, a computational approach to predict single-cell RNA composition from bulk analysis data. This allows for identification of chemoresistant cells and targeted therapy selection, improving treatment outcomes for patients.
Researchers at St. Jude uncover how ABCG2 protein removes chemotherapies from cells, highlighting a potential path to combat drug resistance. The study identifies key amino acids responsible for this promiscuity and suggests designing inhibitors targeting these sites.
Chronic disease medications impair the body's ability to regulate core temperature, increasing the risk of heat-related illness in elderly patients. Exercise and improved fitness levels can help mitigate these effects, but bodily impairments from chemotherapy and medications may limit exercise capacity.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
Researchers have made a significant discovery in gene therapy, showing that genetically engineered blood stem cells can be created while still in the bone marrow. This approach eliminates the need for chemotherapy and transplantation of corrected cells, cutting costs and improving access to critical treatments.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
A new study published in JNCCN found that the adoption of clinical research results led to a significant increase in the use of shorter adjuvant chemotherapy periods, with CAPOX becoming more widely used. The study also revealed disparities in treatment patterns, with Black patients being more likely to receive shorter chemotherapy reg...
A study found that breast cancer patients with higher body mass index (BMI) are more likely to experience heart damage, or cardiotoxicity, during chemotherapy. The study suggests that addressing obesity and considering the potential risk of cardiotoxicity requires a comprehensive approach.
Brigham researchers use induced pluripotent stem cells to restore hormone production and fertility in mice with premature ovarian failure. The study shows promise for treating incurable conditions and may lead to new therapies for patients with ovarian failure.
Scientists identified a process by which enzymes help prevent heart damage in chemotherapy patients. Enzymes normally found in mitochondria move to the nucleus, keeping cells alive. This discovery suggests new methods for testing individual patient responses and potentially preventing heart damage from chemotherapy.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
The updated guidelines urge the clinical use of validated geriatric assessments (GA) to guide treatments in patients aged 65 and older. This approach often results in de-escalation or reduction of therapies, reducing side effects and improving quality of life without compromising survival odds.
A synoptic report improved the completeness of pretreatment CT reports in patients with advanced ovarian cancer. Involvement of surgically established unresectable or challenging-to-resect disease sites was mentioned in all disease-specific synoptic reports, compared to 37% of simple structured reports.
Researchers at the University of Alberta have discovered a correlation between chemotherapy-induced changes to gut bacteria and unhealthy weight gain in breast cancer patients. The study found that these patients gained abdominal fat and experienced inflammation, with significant changes to their gut microbiome.
Researchers have identified a biomarker called CXCL-9 that can be used to diagnose acute tubulointerstitial nephritis (AIN), a condition causing inflammation of the kidneys. The biomarker can be detected via a simple urine test, potentially reducing the need for kidney biopsies.
Researchers at Moffitt Cancer Center found that higher c-reactive protein levels were associated with greater depression and less physical activity among patients with gynecologic cancers. However, most inflammatory markers were not linked to treatment-related symptoms.
A Mayo Clinic study reveals that minimally invasive surgical procedure staging laparoscopy can identify cancer spread early and determine the stage of pancreatic cancer. The research found a higher risk of cancer spread in patients with certain factors, such as age and tumor markers.
Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.
Research suggests that glioblastoma cells possess large-scale coordination, allowing them to respond unison to therapies. Disrupting this organization may result in more powerful treatments for brain tumors.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.
Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.
Researchers found that combining radiation with a genetically engineered oncolytic vaccinia virus improved treatment outcomes for glioblastoma brain tumors in mice. The combination showed a 15% cure rate and 62% rejection of new cancer cells, outperforming radiation alone.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
Researchers from Medical College of Wisconsin found that older breast cancer survivors, particularly those exposed to chemotherapy, showed greater epigenetic aging than their same-aged peers without cancer. This acceleration in biological aging may be associated with worse functional outcomes and quality of life for these patients.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
Researchers created a new type of wound dressing material using advanced polymers, enabling customized dressings with fine-tuned surface adhesion. The material has potential applications in burn treatment and drug delivery for cancer patients, providing constant medication release outside the clinic setting.
Erdafitinib achieves tumor-agnostic benefits across 16 cancer types, including urothelial, lung, and other cancers. The trial demonstrated a disease control rate of 73.7% and clinical benefit rate of 45.6%, with notable improvements in pancreatic and cholangiocarcinoma patients.
The Phase 3 S1826 trial demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma treated with nivolumab and chemotherapy. The therapy was well-tolerated, with few serious immune-related side effects.
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
The nucleus is metabolically active and uses antioxidant enzymes to repair DNA damage. Cells relocate mitochondrial machinery to the nucleus in response to DNA damage, highlighting a paradigm shift in cellular biology.
A large study tracked CIPN in over 1,100 breast cancer patients treated with taxanes, showing persistent sensory and motor symptoms with more severe symptoms with paclitaxel than docetaxel. The study defines a risk prediction model to help doctors individualize patient care.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
UMC Utrecht researchers are conducting two new projects to treat cancer using image-guided interventions. One project uses MRI-guided radiotherapy for locally advanced pancreatic cancer, while the other employs ultrasound techniques for head and neck cancers.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
Researchers at USC Norris Comprehensive Cancer Center have identified a biomarker, CX3CR1, that can predict which patients with non-small cell lung cancer will respond well to chemoimmunotherapy. Elevated levels of the biomarker in T-cells after six to nine weeks of treatment indicate long-term benefits from the combination therapy.
Researchers from Amsterdam UMC and Copenhagen University have found that a chemofree drug-combination therapy is more effective than traditional chemotherapy in treating CLL, resulting in reduced side effects and improved patient outcomes. The study, the largest ever conducted on CLL, involved 920 fit patients and showed that treatment...
A recent clinical trial showed that cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer, improving their quality of life. The treatment also reduced symptoms such as pain and cough, and delayed clinically meaningful deterioration.